This trial is active, not recruiting.

Condition myocardial infarction
Treatment computed tomography late enhancement imaging
Sponsor University of Edinburgh
Start date October 2013
End date December 2015
Trial size 40 participants
Trial identifier NCT02364687, 13/SS/0152


Detecting scarred heart muscle is important to diagnose and treat of a wide variety of heart conditions. Magnetic resonance imaging (MRI) can assess scarred heart muscle but it is time consuming, contraindicated for some patients and not tolerated by others. Computed tomography (CT) imaging has the potential to provide a rapid comprehensive assessment of the heart. This study will assess CT imaging of the heart muscle of patients who have previously undergone MRI of their heart. Using a state of the art CT scanner the investigators will develop a low radiation dose protocol to identify scarred heart muscle. The investigators will use and develop software techniques to analyse these images. This will enable us to develop a new way to identify and measure scarred heart muscle that will benefit patients with heart disease.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model case-only
Time perspective cross-sectional
Participants will have previously had an MRI scan and will undergo a CT scan.
computed tomography late enhancement imaging

Primary Outcomes

Myocardial late enhancement
time frame: Immediate

Eligibility Criteria

Male or female participants at least 40 years old.

Inclusion Criteria: - Presence of late enhancement on magnetic resonance imaging Exclusion Criteria: - age less than 40 - inability or unwillingness to undergo CT - renal failure (serum creatinine >200 umol/l or estimated glomerular filtration rate <30 ml/min) - hepatic failure - allergy to iodinated contrast - pregnancy - breast feeding - inability to undergo informed consent - fast atrial fibrillation

Additional Information

Official title Optimisation and Quantification of Contrast Enhanced Computed Tomography
Principal investigator Michelle Williams
Trial information was received from ClinicalTrials.gov and was last updated in November 2016.
Information provided to ClinicalTrials.gov by University of Edinburgh.